Thrombocytopenia is a decrease in the platelet count below 150,000 in a microliter of blood, i.e., below the lower limit of the reference range, which is 150,000-400,000/μL. The phenomenon of thrombocytopenia related to heavy drinking began to arouse interest in the 1960s and 1970s. It was initially described in case reports and clinical studies on small groups. In the following years, the phenomenon itself and the significance of alcohol-induced thrombocytopenia was studied. Many methodological difficulties inhibiting objective conclusions from research were encountered. Model pathological mechanisms of alcohol thrombocytopenia and the effects of alcohol on the structure and function of platelets were described. Furthermore, the phenomenon of rapid normalization of the number of platelets in people who stopped drinking was described. Relationships between alcohol use, its intensity and occurrence, and intensity of thrombocytopenia have been demonstrated. Predictive platelet counts for alcohol withdrawal syndrome complications have been proven and calculated. The risk of occurrence of withdrawal seizures or delirium tremens in alcohol withdrawal syndrome increases significantly when the platelet count is less than 119,000/μL. The knowledge of the nature of the phenomenon of alcohol-induced thrombocytopenia in a clinical environment allows decisions that are more rational. The attention of clinicians should be drawn to the importance of results of blood tests routinely collected on admission.

Background: The potential risks of increased alcohol use and of the development of alcohol dependence during COVID-19 pandemic were identified. So far there have been no studies concerning pandemic influence on alcohol consumption in medical professionals in quarantine or isolation. Methods: The 12 point ‘online’ ALCOVID survey with a cover letter was designed and addressed to physicians, recruited online via accessible networks, who underwent isolation or quarantine during recent pandemic. The AUDIT-3 scale was included. Results: A representative trial of 113 physicians participated in the study. Over 53% of screened doctors revealed that the amounts of the consumed alcohol have escalated; almost 20% of subjects binged over seven standard drinks for one occasion. Close to every second used six or more drinks on one occasion. Over 40% used alcohol more than four times per week. Female used alcohol more often and more standard drinks per occasion. Male binged more. Anxiety and hopelessness were the most common motives to drink. Conclusions: Alcohol consumption in physicians in quarantine has threateningly increased. It is important to identify the group of people at the risk of problem drinking and dependence development, especially when it concerns key professional branches in the fight against the current crisis.

Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder in children and adults. In the substance use disorders (SUDs) population, ADHD prevalence reaches 23.1%, leading to more severe substance abuse progression and reduced treatment effectiveness. Cannabis is the most common illicit drug used among the ADHD population.

Methylphenidate (MPH) is a central nervous system stimulant that is approved and widely used for the treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy. It acts primarily by inhibiting the reuptake of dopamine and norepinephrine, thereby enhancing synaptic concentrations of these neurotransmitters and improving attention, impulse control, and wakefulness. Despite its well-established therapeutic efficacy, MPH is associated with a complex safety profile that necessitates careful consideration, particularly in long-term use and in populations with preexisting health conditions. Cardiovascular risks, including increased heart rate, elevated blood pressure, and, in rare cases, serious adverse events such as myocardial infarction, arrhythmias, and sudden cardiac death, have been reported. Psychiatric adverse effects, including anxiety, agitation, psychotic symptoms, and exacerbation of preexisting mood disorders, also warrant close monitoring. Additionally, MPH has the potential for misuse, abuse, and dependence, particularly due to its dopaminergic effects, which can contribute to reinforcement and addiction-related behaviors. This review synthesizes current evidence on the safety of MPH, with a focus on its impact on cardiovascular and psychiatric health, and addiction potential. Special attention is given to vulnerable populations, including children, adolescents, individuals with comorbid psychiatric or cardiovascular conditions, and those with a history of substance use disorders. Furthermore, sex and gender influence health outcomes, for MPH healthcare strategies have been addressed. Given these concerns, the necessity for rigorous patient monitoring, individualized risk assessment, and adherence to prescribing guidelines is emphasized to optimize therapeutic outcomes while minimizing risks. Clinical trial number: Not applicable.

Factors Influencing Patient Satisfaction with Healthcare Services in Poland - Article abstract #948225

The association of thrombocytopenia (TP) and alcohol use has been demonstrated. Also TP as possible risk factor for alcohol withdrawal complications (cAWS) have been reported. In this study, the relationship between the presence of TP and cAWS was clearly established and assessed below what platelets count (<119k/mL) this risk increases.